Concurrent targeting of eicosanoid receptor 1/eicosanoid receptor 4 receptors and COX-2 induces synergistic apoptosis in Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus associated non-Hodgkin lymphoma cell lines

Translational Research

Volumn 161, Issue 6, 2013, Pages 447-468

  Paul, Arun George ^a,b   Chandran, Bala ^a   Sharma Walia, Neelam ^a  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b St Francis Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 ISOPROPOXY 9 OXO 2 XANTHENECARBOXYLIC ACID; 8 CHLORO N2 [3 (FURFURYLTHIO)PROPIONYL]DIBENZ[B,F][1,4]OXAZEPINE 10(11H) CARBOHYDRAZIDE; CELECOXIB; CYCLOOXYGENASE 2; EICOSANOID RECEPTOR 1; EICOSANOID RECEPTOR 4; GW 627368 X; GW 627368X; PROSTAGLANDIN E2; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; RECEPTOR; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; EPSTEIN BARR VIRUS; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 8; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; UPREGULATION;

EID: 84878054278     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2013.02.008     Document Type: Article

References (121)

1. R.T. Greenlee, M.B. Hill-Harmon, T. Murray, and M. Thun Cancer statistics, 2001 CA Cancer J Clin 51 2001 15 36 (Pubitemid 32166444)
2. H. Hjalgrim, and E.A. Engels Infectious aetiologyof Hodgkin and non-Hodgkin lymphomas: a review of the epidemiological evidence J Intern Med 264 2008 537 548
3. D.V. Ablashi, L.G. Chatlynne, J.E. Whitman Jr., and E. Cesarman Spectrum of Kaposi's sarcoma-associated herpesvirus, or human herpesvirus 8, diseases Clin Microbiol Rev 15 2002 439 464 (Pubitemid 34761352)
4. A. Carbone, E. Cesarman, M. Spina, A. Gloghini, and T.F. Schulz HIV-associated lymphomas and gamma-herpesviruses Blood 113 2009 1213 1224
5. A. Carbone, and A. Gloghini HHV-8-associated lymphoma: state-of-the-art review Acta Haematol 117 2007 129 131 (Pubitemid 46496795)
6. D. Ganem KSHV and Kaposi's sarcoma: the end of the beginning? Cell 91 1997 157 160 (Pubitemid 27456383)
7. D. Ganem KSHV infection and the pathogenesis of Kaposi's sarcoma Annu Rev Pathol 1 2006 273 296
8. C.M. Klass, and M.K. Offermann Targeting human herpesvirus-8 for treatment of Kaposi's sarcoma and primary effusion lymphoma Curr Opin Oncol 17 2005 447 455 (Pubitemid 41224925)
9. F. Curreli, A.E. Friedman-Kien, and O. Flore Glycyrrhizic acid alters Kaposi sarcoma-associated herpesvirus latency, triggering p53-mediated apoptosis in transformed B lymphocytes J Clin Invest 115 2005 642 652 (Pubitemid 40322238)
10. J. An, Y. Sun, M. Fisher, and M.B. Rettig Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas Leukemia 18 2004 1699 1704 (Pubitemid 39386350)
11. N.L. Toomey, V.V. Deyev, and C. Wood Induction of a TRAIL-mediated suicide program by interferon alpha in primary effusion lymphoma Oncogene 20 2001 7029 7040 (Pubitemid 33052195)
12. G. Sarek, S. Kurki, and J. Enback Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas J Clin Invest 117 2007 1019 1028 (Pubitemid 46556758)
13. L. Hocqueloux, F. Agbalika, E. Oksenhendler, and J.M. Molina Long-term remission of an AIDS-related primary effusion lymphoma with antiviral therapy Aids 15 2001 280 282 (Pubitemid 32142309)
14. M. Luppi, R. Trovato, and P. Barozzi Treatment of herpesvirus associated primary effusion lymphoma with intracavity cidofovir Leukemia 19 2005 473 476 (Pubitemid 40403333)
15. T.R. Halfdanarson, S.N. Markovic, U. Kalokhe, and M. Luppi A non-chemotherapy treatment of a primary effusion lymphoma: durable remission after intracavitary cidofovir in HIV negative PEL refractory to chemotherapy Ann Oncol 17 2006 1849 1850 (Pubitemid 44884063)
16. A.P. Bhatt, P.M. Bhende, S.H. Sin, D. Roy, D.P. Dittmer, and B. Damania Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas Blood 115 2010 4455 4463
17. M.P. Bernard, S. Bancos, P.J. Sime, and R.P. Phipps Targeting cyclooxygenase-2 in hematological malignancies: rationale and promise Curr Pharm Des 14 2008 2051 2060
18. Y.S. Bakhle COX-2 and cancer: a new approach to an old problem Br J Pharmacol 134 2001 1137 1150 (Pubitemid 33097242)
19. M.A. Hull Cyclooxygenase-2: how good is it as a target for cancer chemoprevention? Eur J Cancer 41 2005 1854 1863 (Pubitemid 41557673)
20. M.A. Hull, S.C. Ko, and G. Hawcroft Prostaglandin EP receptors: targets for treatment and prevention of colorectal cancer? Molecular cancer therapeutics 3 2004 1031 1039 (Pubitemid 39199598)
21. M.K. Jones, I.L. Szabo, H. Kawanaka, S.S. Husain, and A.S. Tarnawski von Hippel Lindau tumor suppressor and HIF-1alpha: new targets of NSAIDs inhibition of hypoxia-induced angiogenesis Faseb J 16 2002 264 266
22. M.K. Jones, H. Wang, and B.M. Peskar Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing Nat Med 5 1999 1418 1423
23. M. Kaur Saini, J. Kaur, P. Sharma, and S. Nath Sanyal Chemopreventive response of diclofenac, a nonsteroidal anti-inflammatory drug in experimental carcinogenesis Nutr Hosp 24 2009 717 723
24. W.T. Chen, W.C. Hung, and W.Y. Kang Overexpression of cyclooxygenase-2 in urothelial carcinoma in conjunction with tumor-associated-macrophage infiltration, hypoxia-inducible factor-1alpha expression, and tumor angiogenesis Apmis 117 2009 176 184
25. M. Kobayashi, S. Nakamura, and K. Shibata Etodolac inhibits EBER expression and induces Bcl-2-regulated apoptosis in Burkitt's lymphoma cells Eur J Haematol 75 2005 212 220 (Pubitemid 41153101)
26. H. He, H.H. Xia, and J.D. Wang Inhibition of human telomerase reverse transcriptase by nonsteroidal anti-inflammatory drugs in colon carcinoma Cancer 106 2006 1243 1249 (Pubitemid 43363900)
27. Q. He, X. Luo, and W. Jin Celecoxib and a novel COX-2 inhibitor ON09310 upregulate death receptor 5 expression via GADD153/CHOP Oncogene 27 2008 2656 2660 (Pubitemid 351550874)
28. L. Liu, R. Li, and Y. Pan High-throughput screen of protein expression levels induced by cyclooxygenase-2 during influenza a virus infection Clin Chim Acta 412 2011 1081 1085
29. J.Y. Li, X.Z. Wang, F.L. Chen, J.P. Yu, and H.S. Luo Nimesulide inhibits proliferation via induction of apoptosis and cell cycle arrest in human gastric adenocarcinoma cell line World J Gastroenterol 9 2003 915 920
30. M. Ladetto, S. Vallet, and A. Trojan Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome Blood 105 2005 4784 4791 (Pubitemid 40807304)
31. S. Zha, V. Yegnasubramanian, W.G. Nelson, W.B. Isaacs, and A.M. De Marzo Cyclooxygenases in cancer: progress and perspective Cancer Lett 215 2004 1 20 (Pubitemid 39221453)
32. D. Wang, and R.N. Dubois Prostaglandins and cancer Gut 55 2006 115 122 (Pubitemid 41820645)
33. M.D. Castellone, H. Teramoto, B.O. Williams, K.M. Druey, and J.S. Gutkind Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis Science 310 2005 1504 1510 (Pubitemid 41746348)
34. A.M. Fulton, X. Ma, and N. Kundu Targeting prostaglandin E EP receptors to inhibit metastasis Cancer Res 66 2006 9794 9797 (Pubitemid 44672027)
35. M. Majima, H. Amano, and I. Hayashi Prostanoid receptor signaling relevant to tumor growth and angiogenesis Trends Pharmacol Sci 24 2003 524 529 (Pubitemid 37244005)
36. E. Piazuelo, P. Jimenez, and M. Strunk Effects of selective PGE2 receptor antagonists in esophageal adenocarcinoma cells derived from Barrett's esophagus Prostaglandins Other Lipid Mediat 81 2006 150 161 (Pubitemid 44666498)
37. Y. Sugimoto, and S. Narumiya Prostaglandin E receptors J Biol Chem 282 2007 11613 11617 (Pubitemid 47100657)
38. J. Wang, K. Wu, and F. Bai Celecoxib could reverse the hypoxia-induced Angiopoietin-2 upregulation in gastric cancer Cancer Lett 242 2006 20 27 (Pubitemid 44485293)
39. N. Sharma-Walia, A.G. Paul, and V. Bottero Kaposi's sarcoma associated herpes virus (KSHV) induced COX-2: a key factor in latency, inflammation, angiogenesis, cell survival and invasion PLoS Pathog 6 2010 e1000777
40. A.G. Paul, N. Sharma-Walia, and B. Chandran Targeting KSHV/HHV-8 latency with COX-2 selective inhibitor nimesulide: a potential chemotherapeutic modality for primary effusion lymphoma PLoS One 6 2011 e24379
41. A. George Paul, N. Sharma-Walia, N. Kerur, C. White, and B. Chandran Piracy of prostaglandin E2/EP receptor-mediated signaling by Kaposi's sarcoma-associated herpes virus (HHV-8) for latency gene expression: strategy of a successful pathogen Cancer research 70 2010 3697 3708
42. N. Sharma-Walia, H. Raghu, and S. Sadagopan Cyclooxygenase 2 induced by Kaposi's sarcoma-associated herpes virus early during in vitro infection of target cells plays a role in the maintenance of latent viral gene expression J Virol 80 2006 6534 6552 (Pubitemid 43927455)
43. N. Sharma-Walia, A.G. Paul, K. Patel, K. Chandran, W. Ahmad, and B. Chandran Nfat and Creb regulate Kaposi's sarcoma associated herpes virus (KSHV) induced cyclooxygenase-2 (Cox-2) J Virol 84 2010 12733 12753
44. N. Sharma-Walia, K. Patel, and K. Chandran COX-2/PGE2: molecular ambassadors of Kaposi's sarcoma-associated herpes virus oncoprotein-vFLIP Oncogenesis 1 2012 1 21 10.1038/oncsis.2012.5
45. J.M. Bock, S.G. Menon, and L.L. Sinclair Celecoxib toxicity is cell cycle phase specific Cancer Res 67 2007 3801 3808 (Pubitemid 46762167)
46. A.H. Schonthal Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy Br J Cancer 97 2007 1465 1468 (Pubitemid 350175844)
47. A.E. Reynolds, and L.W. Enquist Biological interactions between herpesviruses and cyclooxygenase enzymes Rev Med Virol 16 2006 393 403 (Pubitemid 44763840)
48. B.D. Shelby, A. Nelson, and C. Morris Gamma-herpesvirus neoplasia: a growing role for COX-2 Microsc Res Tech 68 2005 120 129 (Pubitemid 41696964)
49. K. Takada, K. Horinouchi, and Y. Ono An Epstein-Barr virus-producer line Akata: establishment of the cell line and analysis of viral DNA Virus Genes 5 1991 147 156
50. N. Yamamoto, T. Takizawa, Y. Iwanaga, N. Shimizu, and N. Yamamoto Malignant transformation of B lymphoma cell line BJAB by Epstein-Barr virus-encoded small RNAs FEBS Lett 484 2000 153 158
51. R.J. Keery, and P. Lumley AH6809, a prostaglandin DP-receptor blocking drug on human platelets Br J Pharmacol 94 1988 745 754
52. R.J. Wilson, G.M. Giblin, and S. Roomans GW627368X (N-{2-[4-(4,9- diethoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl] acetyl} benzene sulphonamide): a novel, potent and selective prostanoid EP4 receptor antagonist Br J Pharmacol 148 2006 326 339 (Pubitemid 43801180)
53. N. Foudi, L. Kotelevets, and L. Louedec Vasorelaxation induced by prostaglandin E2 in human pulmonary vein: role of the EP4 receptor subtype Br J Pharmacol 154 2008 1631 1639
54. S. Shi, and U. Klotz Clinical use and pharmacological properties of selective COX-2 inhibitors Eur J Clin Pharmacol 64 2008 233 252
55. A. Kardosh, W. Wang, and J. Uddin Dimethyl-celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-inhibitory function, potently mimics the anti-tumor effects of celecoxib on Burkitt's lymphoma in vitro and in vivo Cancer Biol Ther 4 2005 571 582 (Pubitemid 41351232)
56. K. Jones, C. Rivera, and C. Sgadari Infection of human endothelial cells with Epstein-Barr virus J Exp Med 182 1995 1213 1221
57. P. McGettigan, and D. Henry Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2 JAMA 296 2006 1633 1644 (Pubitemid 44511610)
58. P. Sarita Rajender, D. Ramasree, K. Bhargavi, M. Vasavi, and V. Uma Selective inhibition of proteins regulating CDK/cyclin complexes: strategy against cancer-a review J Recept Signal Transduct Res 30 2010 206 213
59. D.I. Smith, Y. Zhu, S. McAvoy, and R. Kuhn Common fragile sites, extremely large genes, neural development and cancer Cancer Lett 232 2006 48 57 (Pubitemid 43053933)
60. J. Martin, M.V. St-Pierre, and J.F. Dufour Hit proteins, mitochondria and cancer Biochim Biophys Acta 1807 2011 626 632
61. G. Murphy Tissue inhibitors of metalloproteinases Genome Biol 12 2011 233
62. Y.C. Liao, and S.H. Lo Deleted in liver cancer-1 (DLC-1): a tumor suppressor not just for liver Int J Biochem Cell Biol 40 2008 843 847 (Pubitemid 351329658)
63. T. Sperka, J. Wang, and K.L. Rudolph DNA damage checkpoints in stem cells, ageing and cancer Nat Rev Mol Cell Biol 13 2012 579 590
64. C. Zhao, and X. Bu Promoter methylation of tumor-related genes in gastric carcinogenesis Histol Histopathol 27 2012 1271 1282
65. J.H. Overmeyer, and W.A. Maltese Death pathways triggered by activated Ras in cancer cells Front Biosci 16 2011 1693 1713
66. G.L. Semenza Molecular mechanisms mediating metastasis of hypoxic breast cancer cells Trends Mol Med 18 2012 534 543
67. M. Esteller Profiling aberrant DNA methylation in hematologic neoplasms: a view from the tip of the iceberg Clin Immunol 109 2003 80 88 (Pubitemid 37324745)
68. V. Dehennaut, and D. Leprince Implication of HIC1 (Hypermethylated In Cancer 1) in the DNA damage response Bull Cancer 96 2009 E66 E72
69. K. Szymanska, and P. Hainaut TP53 and mutations in human cancer Acta Biochim Pol 50 2003 231 238 (Pubitemid 37034245)
70. R.W. Craig MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis Leukemia 16 2002 444 454 (Pubitemid 34449724)
71. J. Paredes, J. Figueiredo, and A. Albergaria Epithelial E- and P-cadherins: role and clinical significance in cancer Biochim Biophys Acta 1826 2012 297 311
72. B. Ehlin-Henriksson, F. Mowafi, G. Klein, and A. Nilsson Epstein-Barr virus infection negatively impacts the CXCR4-dependent migration of tonsillar B cells Immunology 117 2006 379 385
73. J. Yuan, E. Cahir-McFarland, B. Zhao, and E. Kieff Virus and cell RNAs expressed during Epstein-Barr virus replication J Virol 80 2006 2548 2565 (Pubitemid 43271560)
74. I.K. Ruf, P.W. Rhyne, and H. Yang Epstein-barr virus regulates c-MYC, apoptosis, and tumorigenicity in Burkitt lymphoma Mol Cell Biol 19 1999 1651 1660 (Pubitemid 29098224)
75. I.K. Ruf, P.W. Rhyne, and H. Yang EBV regulates c-MYC, apoptosis, and tumorigenicity in Burkitt's lymphoma Curr Top Microbiol Immunol 258 2001 153 160 (Pubitemid 32574039)
76. D.L. Di Bartolo, M. Cannon, and Y.F. Liu KSHV LANA inhibits TGF-beta signaling through epigenetic silencing of the TGF-beta type II receptor Blood 111 2008 4731 4740
77. Y.C. Shin, H. Nakamura, and X. Liang Inhibition of the ATM/p53 signal transduction pathway by Kaposi's sarcoma-associated herpesvirus interferon regulatory factor 1 J Virol 80 2006 2257 2266 (Pubitemid 43271532)
78. K.L. Fries, W.E. Miller, and N. Raab-Traub Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene J Virol 70 1996 8653 8659 (Pubitemid 26378446)
79. J.L. Kenney, M.E. Guinness, M. Reiss, and J. Lacy Antisense to the Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP-1) sensitizes EBV-immortalized B cells to transforming growth factor-beta and chemotherapeutic agents Int J Cancer 91 2001 89 98
80. A. Polack, K. Hortnagel, and A. Pajic c-myc activation renders proliferation of Epstein-Barr virus (EBV)-transformed cells independent of EBV nuclear antigen 2 and latent membrane protein 1 Proc Natl Acad Sci U S A 93 1996 10411 10416
81. C. Man, J. Rosa, and L.T. Lee Latent membrane protein 1 suppresses RASSF1A expression, disrupts microtubule structures and induces chromosomal aberrations in human epithelial cells Oncogene 26 2007 3069 3080 (Pubitemid 46733640)
82. K. Matsusaka, A. Kaneda, and G. Nagae Classification of Epstein-Barr virus-positive gastric cancers by definition of DNA methylation epigenotypes Cancer Res 71 2011 7187 7197
83. G.H. Kang, S. Lee, and W.H. Kim Epstein-barr virus-positive gastric carcinoma demonstrates frequent aberrant methylation of multiple genes and constitutes CpG island methylator phenotype-positive gastric carcinoma Am J Pathol 160 2002 787 794 (Pubitemid 34224568)
84. J.L. Ryan, R.J. Jones, and S.C. Kenney Epstein-Barr virus-specific methylation of human genes in gastric cancer cells Infect Agent Cancer 5 2010 27
85. D.C. Lee, D.T. Chua, W.I. Wei, J.S. Sham, and A.S. Lau Induction of matrix metalloproteinases by Epstein-Barr virus latent membrane protein 1 isolated from nasopharyngeal carcinoma Biomed Pharmacother 61 2007 520 526 (Pubitemid 47570077)
86. J. Kim, H.S. Lee, S.I. Bae, Y.M. Lee, and W.H. Kim Silencing and CpG island methylation of GSTP1 is rare in ordinary gastric carcinomas but common in Epstein-Barr virus-associated gastric carcinomas Anticancer Res 25 2005 4013 4019 (Pubitemid 41665179)
87. Q. Zhou, M. Olivo, K.Y. Lye, S. Moore, A. Sharma, and B. Chowbay Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models Cancer Chemother Pharmacol 56 2005 569 577 (Pubitemid 41425052)
88. S.H. Hutajulu, S.R. Indrasari, and L.P. Indrawati Epigenetic markers for early detection of nasopharyngeal carcinoma in a high risk population Mol Cancer 10 2011 48
89. T.J. Seng, J.S. Low, and H. Li The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation Oncogene 26 2007 934 944
90. Y. Dai, Y. Tang, and F. He Screening and functional analysis of differentially expressed genes in EBV-transformed lymphoblasts Virol J 9 2012 77
91. B. Shan, C.A. Morris, Y. Zhuo, B.D. Shelby, D.R. Levy, and J.A. Lasky Activation of proMMP-2 and Src by HHV8 vGPCR in human pulmonary arterial endothelial cells J Mol Cell Cardiol 42 2007 517 525 (Pubitemid 46357551)
92. B. Chandran Early events in Kaposi's sarcoma-associated herpesvirus infection of target cells J Virol 84 2010 2188 2199
93. X. Wang, and R.D. Klein Prostaglandin E2 induces vascular endothelial growth factor secretion in prostate cancer cells through EP2 receptor-mediated cAMP pathway Mol Carcinog 46 2007 912 923 (Pubitemid 350058411)
94. O. Hatton, S.L. Lambert, S.M. Krams, and O.M. Martinez Src kinase and Syk activation initiate PI3K signaling by a chimeric latent membrane protein 1 in Epstein-Barr virus (EBV)+ B cell lymphomas PLoS One 7 2012 e42610
95. J.A. Fotheringham, N.E. Coalson, and N. Raab-Traub Epstein-Barr virus latent membrane protein-2A induces ITAM/Syk- and Akt-dependent epithelial migration through alphav-integrin membrane translocation J Virol 86 2012 10308 10320
96. D.E. de Oliveira, G. Ballon, and E. Cesarman NF-kappaB signaling modulation by EBV and KSHV Trends Microbiol 18 2010 248 257
97. A.M. Flanagan, and A. Letai BH3 domains define selective inhibitory interactions with BHRF-1 and KSHV BCL-2 Cell Death Differ 15 2008 580 585
98. M. Pietrek, M.M. Brinkmann, and I. Glowacka Role of the Kaposi's sarcoma-associated herpesvirus K15 SH3 binding site in inflammatory signaling and B-cell activation J Virol 84 2010 8231 8240
99. B.S. Lee, S.H. Lee, P. Feng, H. Chang, N.H. Cho, and J.U. Jung Characterization of the Kaposi's sarcoma-associated herpesvirus K1 signalosome J Virol 79 2005 12173 12184 (Pubitemid 41346079)
100. T. Yokoi, T. Miyawaki, A. Yachie, K. Kato, Y. Kasahara, and N. Taniguchi Epstein-Barr virus-immortalized B cells produce IL-6 as an autocrine growth factor Immunology 70 1990 100 105 (Pubitemid 20148070)
101. S.C. Todd, and C.D. Tsoukas EBV induces proliferation of immature human thymocytes in an IL-2-mediated response J Immunol 156 1996 4217 4223 (Pubitemid 26165818)
102. A.L. Burkhardt, J.B. Bolen, E. Kieff, and R. Longnecker An Epstein-Barr virus transformation-associated membrane protein interacts with src family tyrosine kinases J Virol 66 1992 5161 5167
103. W. Chen, I.B. Hilton, M.R. Staudt, C.E. Burd, and D.P. Dittmer Distinct p53, p53:LANA, and LANA complexes in Kaposi's Sarcoma-associated Herpesvirus Lymphomas J Virol 84 2010 3898 3908
104. I. Guasparri, H. Wu, and E. Cesarman The KSHV oncoprotein vFLIP contains a TRAF-interacting motif and requires TRAF2 and TRAF3 for signalling EMBO Rep 7 2006 114 119
105. J. Tomeczkowski, E. Yakisan, B. Wieland, A. Reiter, K. Welte, and K.W. Sykora Absence of G-CSF receptors and absent response to G-CSF in childhood Burkitt's lymphoma and B-ALL cells Br J Haematol 89 1995 771 779
106. D. Roy, S.H. Sin, B. Damania, and D.P. Dittmer Tumor suppressor genes FHIT and WWOX are deleted in primary effusion lymphoma (PEL) cell lines Blood 118 2011 e32 e39
107. S. Toujani, P. Dessen, and N. Ithzar High resolution genome-wide analysis of chromosomal alterations in Burkitt's lymphoma PLoS One 4 2009 e7089
108. J. Uchida, T. Yasui, and Y. Takaoka-Shichijo Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses Science 286 1999 300 303 (Pubitemid 29484694)
109. J. Rastelli, C. Homig-Holzel, and J. Seagal LMP1 signaling can replace CD40 signaling in B cells in vivo and has unique features of inducing class-switch recombination to IgG1 Blood 111 2008 1448 1455 (Pubitemid 351213432)
110. D.S. Bellows, M. Howell, C. Pearson, S.A. Hazlewood, and J.M. Hardwick Epstein-Barr virus BALF1 is a BCL-2-like antagonist of the herpesvirus antiapoptotic BCL-2 proteins J Virol 76 2002 2469 2479 (Pubitemid 34150715)
111. W.L. Marshall, C. Yim, and E. Gustafson Epstein-Barr virus encodes a novel homolog of the bcl-2 oncogene that inhibits apoptosis and associates with Bax and Bak J Virol 73 1999 5181 5185 (Pubitemid 29246784)
112. S.M. Gregory, J.A. West, P.J. Dillon, C. Hilscher, D.P. Dittmer, and B. Damania Toll-like receptor signaling controls reactivation of KSHV from latency Proc Natl Acad Sci U S A 106 2009 11725 11730
113. I. Fathallah, P. Parroche, and H. Gruffat EBV latent membrane protein 1 is a negative regulator of TLR9 J Immunol 185 2010 6439 6447
114. E. Ohsaki, K. Ueda, S. Sakakibara, E. Do, K. Yada, and K. Yamanishi Poly(ADP-ribose) polymerase 1 binds to Kaposi's sarcoma-associated herpesvirus (KSHV) terminal repeat sequence and modulates KSHV replication in latency J Virol 78 2004 9936 9946 (Pubitemid 39187112)
115. Y.C. Ko, W.H. Tsai, and P.W. Wang Suppressive regulation of KSHV RTA with O-GlcNAcylation J Biomed Sci 19 2012 12
116. F. Lu, K. Tsai, and H.S. Chen Identification of host-chromosome binding sites and candidate gene targets for Kaposi's sarcoma-associated herpesvirus LANA J Virol 86 2012 5752 5762
117. A. Cusimano, D. Fodera, and N. Lampiasi Prostaglandin E2 receptors and COX enzymes in human hepatocellular carcinoma: role in the regulation of cell growth Ann NY Acad Sci 1155 2009 300 308
118. K.L. Tober, T.A. Wilgus, D.F. Kusewitt, J.M. Thomas-Ahner, T. Maruyama, and T.M. Oberyszyn Importance of the EP(1) receptor in cutaneous UVB-induced inflammation and tumor development J Invest Dermatol 126 2006 205 211 (Pubitemid 43336114)
119. R.A. Gupta, and R.N. DuBois Cyclooxygenase-2 inhibitor therapy for the prevention of esophageal adenocarcinoma in Barrett's esophagus J Natl Cancer Inst 94 2002 406 407 (Pubitemid 34285083)
120. X. Xin, M. Majumder, G.V. Girish, V. Mohindra, T. Maruyama, and P.K. Lala Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model Laboratory Investigation 92 2012 1115 1128
121. T. Singh, S.D. Sharma, and S.K. Katiyar Grape proanthocyanidins induce apoptosis by loss of mitochondrial membrane potential of human nonsmall cell lung cancer cells in vitro and in vivo PLoS One 6 2011 e27444